BioAdaptives

BioAdaptives Market capitalization

The The market capitalization of BioAdaptives (BDPT) as of Oct 25, 2026 is 144,103.53 USD. In the previous year, The market capitalization was 144,103.53 USD — a change of 0.00% (lower).

Market capitalization

144,103.53USD

YoY

0.00%

Last updated:

In 2025, BioAdaptives's market cap stood at 144,103.53 USD, a 0.00% increase from the 144,103.53 USD market cap in the previous year.

The BioAdaptives Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
144,103.53 USD
Jan 1, 2019
144,103.53 USD
Jan 1, 2020
144,103.53 USD
Jan 1, 2021
144,103.53 USD
Jan 1, 2022
144,103.53 USD
Jan 1, 2023
144,103.53 USD
Jan 1, 2024
144,103.53 USD
Jan 1, 2025
144,103.53 USD
The BioAdaptives Market capitalization history
YEARMarket capitalizationYoY
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD0.00%
144,103.53USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring BioAdaptives's Market Capitalization

BioAdaptives's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of BioAdaptives's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

BioAdaptives's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in BioAdaptives’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about BioAdaptives stock

The market capitalization of BioAdaptives is 144,103.53 USD in 2025.

The market capitalization of BioAdaptives changed from 144,103.53 USD to 144,103.53 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioAdaptives

All Key Metrics — BioAdaptives